1.Mackensen-Haen S, Bader R, Grund K, Bohle A: Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clinical nephrology 1981, 15(4):167–171.
2.Klassen DK, Weir MR, Buddemeyer EU: Simultaneous measurements of glomerular filtration rate by two radioisotopic methods in patients without renal impairment. Journal of the American Society of Nephrology 1992, 3(1):108–112.
3.Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A: Global cardiovascular and renal outcomes of reduced GFR. Journal of the American Society of Nephrology 2017, 28(7):2167–2179.
4.Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology 2002, 39(7):1113–1119.
5.Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine 2001, 134(8):629–636.
6.Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, Nahas M, Jaber B, Jadoul M, Levin A: Chronic kidney disease as a global public health problem: approaches and initiatives–a position statement from Kidney Disease Improving Global Outcomes. Kidney international 2007, 72(3):247–259.
7.Kagiyama S, Matsumura K, Ansai T, Soh I, Takata Y, Awano S, Sonoki K, Yoshida A, Takehara T, Iida M: Chronic kidney disease increases cardiovascular mortality in 80-year-old subjects in Japan. Hypertension Research 2008, 31(11):2053.
8.Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of the American College of Cardiology 2003, 41(1):47–55.
9.Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG: Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney international 2000, 57(5):2072–2079.
10.Briganti EM, Branley P, Chadban SJ, Shaw JE, McNeil JJ, Welborn TA, Atkins RC: Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab Kidney Study. American Journal of Kidney Diseases 2002, 40(4):704–712.
11.Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. Jama 2004, 291(7):844–850.
12.Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. Journal of the American Society of Nephrology 2003, 14(11):2934–2941.
13.Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney international 2004, 65(5):1870–1876.
14.Chan C: Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005, 34(1):31–35.
15.Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Influence of smoking and obesity on the development of proteinuria. Kidney international 2002, 62(3):956–962.
16.Bollen KA: Structural equations with latent variables, vol. 210: John Wiley & Sons; 2014.
17.Matsueda RL, Press G: Key advances in the history of structural equation modeling. Handbook of structural equation modeling 2012:17–42.
18.Eghtesad S, Mohammadi Z, Shayanrad A, Faramarzi E, Joukar F, Hamzeh B, Farjam M, Sakhvidi MJZ, Miri-Monjar M, Moosazadeh M: The PERSIAN cohort: providing the evidence needed for healthcare reform. Archives of Iranian medicine 2017, 20(11):691.
19.Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, Mohammadi Z, Mahmoudi Z, Shayanrad A, Roozafzai F: Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): Rationale, objectives, and design. American journal of epidemiology 2017, 187(4):647–655.
20.Pasdar Y, Najafi F, Moradinazar M, Shakiba E, Karim H, Hamzeh B, Nelson M, Dobson A: Cohort profile: Ravansar Non-Communicable Disease cohort study: the first cohort study in a Kurdish population. International journal of epidemiology 2019.
21.Organization WH: Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. 2011.
22.Bryant CX, Green DJ: ACE lifestyle & weight management consultant manual: the ultimate resource for fitness professionals: American Council on Exercise; 2007.
23.Expert Panel on Detection E: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama 2001, 285(19):2486.
24.Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, Ikizler TA, Johnson CA, Kausz A, Kimmel PL, Kusek J: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 2002, 39(2 SUPPL. 1).
25.Levey A: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000, 11:A0828.
26.Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine 1999, 130(6):461–470.
27.VII J: Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure JAMA 2003, 289:2560–2572.
28.Organization WH: Diabetes mellitus. Report of a WHO study group. WHO Technical Report 1985.
29.Ikewuchi JC, Ikewuchi CC, Ifeanacho MO: Attenuation of salt-loading induced cardiomegaly and dyslipidemia in Wistar rats by aqueous leaf extract of Chromolaena odorata. Pharmacology & Pharmacy 2014, 5(02):160.
30.Cohen P, West SG, Aiken LS: Applied multiple regression/correlation analysis for the behavioral sciences: Psychology Press; 2014.
31.Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Current opinion in nephrology and hypertension 2004, 13(1):73–81.
32.Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Investigators T: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology 2008, 51(15):1448–1454.
33.Wuerzner G, Pruijm M, Maillard M, Bovet P, Renaud C, Burnier M, Bochud M: Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. American Journal of Kidney Diseases 2010, 56(2):303–312.
34.Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, Sattar N, Zukowska-Szczechowska E, Dominiczak AF: Glomerular hyperfiltration: a new marker of metabolic risk. Kidney international 2007, 71(8):816–821.
35.Chandrajay D: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. In.: SAGE Publications Sage UK: London, England; 2010.
36.Stengel B, Tarver–Carr ME, Powe NR, Eberhardt MS, Brancati FL: Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003, 14(4):479–487.
37.Stenvinkel P, Zoccali C, Ikizler TA: Obesity in CKD—what should nephrologists know? Journal of the American Society of Nephrology 2013, 24(11):1727–1736.
38.Usberti M, Federico S, Di Minno G, Ungaro B, Ardillo G, Pecoraro C, Cianciaruso B, Cerbone AM, Cirillo F, Pannain M: Effects of angiotensin II on plasma ADH, prostaglandin synthesis, and water excretion in normal humans. American Journal of Physiology-Renal Physiology 1985, 248(2):F254-F259.
39.Sharkey L: Kidney Function Tests. Interpretation of Equine Laboratory Diagnostics 2017:39.
40.Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003, 41(6):1341–1345.
41.Hsu C-y, McCulloch CE, Darbinian J, Go AS, Iribarren C: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Archives of internal medicine 2005, 165(8):923–928.
42.Huang Y, Cai X, Zhang J, Mai W, Wang S, Hu Y, Ren H, Xu D: Prehypertension and incidence of ESRD: a systematic review and meta-analysis. American Journal of Kidney Diseases 2014, 63(1):76–83.
43.Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008, 196(2):823–834.
44.Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney international 1988, 33(5).